Show simple item record

dc.contributor.authorJackson, Alan
dc.contributor.authorJayson, Gordon C
dc.contributor.authorLi, K L
dc.contributor.authorZhu, X P
dc.contributor.authorCheckley, D R
dc.contributor.authorTessier, J J L
dc.contributor.authorWaterton, John C
dc.date.accessioned2009-08-28T08:40:10Z
dc.date.available2009-08-28T08:40:10Z
dc.date.issued2003-03
dc.identifier.citationReproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. 2003, 76 (903):153-62 Br J Radiolen
dc.identifier.issn0007-1285
dc.identifier.pmid12684231
dc.identifier.doi10.1259/bjr/70653746
dc.identifier.urihttp://hdl.handle.net/10541/79035
dc.description.abstractWe have investigated the reproducibility of dynamic contrast enhanced imaging techniques in nine patients with cerebral glioma. Patients were imaged twice with a 2 day interval between scans. Maps were produced of the time taken to achieve 90% enhancement (T90), the maximal intensity change per time interval ratio (MITR), the volume transfer coefficient between plasma and the extravascular extracellular space (K(trans)) and the extravascular extracellular contrast distribution volume, v(e). Measurements of K(trans) greater than 1.2 min(-1) were used to exclude pixels where first pass perfusion effects dominated the measurement. Measures of the test-retest coefficient of variation (CoV) and intraclass correlation coefficients were used to assess reproducibility for measurements from a volume of interest containing enhancing tissue from the whole tumour. MITR showed poor reproducibility (mean CoV 17.9%, 95% confidence limits for group comparisons 20.2%). T90 showed good reproducibility (mean CoV 7.1%, 95% confidence limits for group comparisons 5.2%). Calculated values of K(trans) and v(e) also showed good reproducibility (mean CoV 7.7% and 6.2% respectively, 95% confidence limits for group comparisons 6.2% and 4.8%, respectively). We conclude that the measurements of K(trans) and v(e) derived from pharmacokinetic analysis are sufficiently reproducible to support their use as a biological markers in therapeutic trials.
dc.language.isoenen
dc.subjectBrain Canceren
dc.subject.meshAged
dc.subject.meshAstrocytoma
dc.subject.meshBrain Neoplasms
dc.subject.meshContrast Media
dc.subject.meshExtracellular Space
dc.subject.meshFemale
dc.subject.meshGlioblastoma
dc.subject.meshHumans
dc.subject.meshImage Enhancement
dc.subject.meshMagnetic Resonance Imaging
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshReproducibility of Results
dc.subject.meshTime Factors
dc.titleReproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma.en
dc.typeArticleen
dc.contributor.departmentDivision of Imaging Science and Biomedical Engineering, Stopford Medical School, University of Manchester, Manchester M13 9PT, UK.en
dc.identifier.journalThe British Journal of Radiologyen
html.description.abstractWe have investigated the reproducibility of dynamic contrast enhanced imaging techniques in nine patients with cerebral glioma. Patients were imaged twice with a 2 day interval between scans. Maps were produced of the time taken to achieve 90% enhancement (T90), the maximal intensity change per time interval ratio (MITR), the volume transfer coefficient between plasma and the extravascular extracellular space (K(trans)) and the extravascular extracellular contrast distribution volume, v(e). Measurements of K(trans) greater than 1.2 min(-1) were used to exclude pixels where first pass perfusion effects dominated the measurement. Measures of the test-retest coefficient of variation (CoV) and intraclass correlation coefficients were used to assess reproducibility for measurements from a volume of interest containing enhancing tissue from the whole tumour. MITR showed poor reproducibility (mean CoV 17.9%, 95% confidence limits for group comparisons 20.2%). T90 showed good reproducibility (mean CoV 7.1%, 95% confidence limits for group comparisons 5.2%). Calculated values of K(trans) and v(e) also showed good reproducibility (mean CoV 7.7% and 6.2% respectively, 95% confidence limits for group comparisons 6.2% and 4.8%, respectively). We conclude that the measurements of K(trans) and v(e) derived from pharmacokinetic analysis are sufficiently reproducible to support their use as a biological markers in therapeutic trials.


This item appears in the following Collection(s)

Show simple item record